Radius Health Reports Fourth Quarter and Full Year 2017 Financial and Operating Results and Provides Business Update

- March 2nd, 2018

Radius Health (Nasdaq:RDUS), reported its financial results for the fourth quarter and full year ended December 31, 2017, and provided a business update. As quoted in the press release: “I’m also very pleased to announce that in January we aligned with the FDA on a regulatory path for our investigational abaloparatide patch, a novel technology … Continued

Radius Health (Nasdaq:RDUS), reported its financial results for the fourth quarter and full year ended December 31, 2017, and provided a business update.

As quoted in the press release:

“I’m also very pleased to announce that in January we aligned with the FDA on a regulatory path for our investigational abaloparatide patch, a novel technology with potential to provide a convenient, alternative treatment option for osteoporosis patients. This innovation is aimed at expanding both the abaloparatide and total anabolic addressable markets. We are also excited to announce that we have entered into a commercial supply agreement with 3M Company under which 3M has agreed to exclusively manufacture commercial supplies of abaloparatide patches,” Mr. Høiland continued.

Click here to read the full press release.

Are You Aware of the FDA's Plans for 2018?

Find out what's going on in our new report
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time

Leave a Reply

Your email address will not be published. Required fields are marked *